CAR T-cell therapy for mesothelioma and other solid tumors
Treatments studied
Part of Blood & lymphatic, Cancer, Digestive system, Hormones & metabolism, Lungs & breathing, Women’s health & pregnancy clinical trials.
This study tests a new kind of immunotherapy called CAR T-cells that are designed to find and attack cancer cells with a protein called mesothelin on their surface. It may help people with mesothelioma or other solid tumors that have not improved with standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have mesothelioma (epithelioid or biphasic type) or another advanced solid tumor that cannot be surgically removed and has spread or come back.
- Your cancer has gotten worse after at least one standard treatment, and there's no limit on how many past treatments you've had.
- You must have at least one measurable tumor that can be checked by scans.
- A biopsy or saved tissue sample must show your cancer cells have a certain amount of mesothelin (scored 2+ or 3+ in at least half the cells).
- You are 18 years or older, feel well enough to be up and about (ECOG 0 or 1), and have adequate heart, lung, liver, kidney, and blood cell function.
- You must not have active infections like HIV or hepatitis B or C, or uncontrolled autoimmune diseases or lung inflammation.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new type of immune cell therapy (CAR T-cells) designed to target cancer cells that have a protein called mesothelin but have lost a marker that lets them hide from the immune system. It's for people with advanced solid tumors who have already tried standard treatments.
This trial tests a new treatment called KT032, a type of CAR-T cell therapy, for people with advanced solid tumors (like ovarian cancer, mesothelioma, or colon cancer) that have spread to the belly lining. The treatment is given as an injection and is designed to target a protein called mesothelin on cancer cells. The goal is to see if it's safe and if it can help shrink tumors.
This trial tests a new type of immune cell therapy made from your own cells (gamma-delta T cells) that are engineered to find and attack cancers that have GPC3 or mesothelin proteins. It may be an option for people with advanced cancer who have not had gene therapy before and are in generally good health.
This trial tests a new type of cell therapy (CAR-T cells) that is designed to find and attack cancer cells showing a protein called mesothelin. It may be an option for people with advanced solid tumors who have exhausted standard treatments.
This Phase 1 trial tests a customized immune therapy (CAR-T cells) for advanced cancers that have the proteins mesothelin, GPC3, and/or GUCY2C. It may help your body better recognize and kill cancer cells, but early-phase trials mainly focus on safety and learning how well the treatment works.
This trial tests a therapy using your own immune cells (T cells) modified to target mesothelin (MSLN), a protein found on some cancer cells. It may help people with certain advanced solid tumors that have not responded to or can't tolerate standard treatments.
Hear when a new Mesothelioma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.